Immunotherapy (e.g., Pembrolizumab, Nivolumab)
Treatment for Esophageal Cancer
Typical Dosage: Pembrolizumab 200 mg IV every 3 weeks or 400 mg IV every 6 weeks.
Effectiveness
65%
Safety Score
45%
Clinical Trials
300
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
Pembrolizumab 200 mg IV every 3 weeks or 400 mg IV every 6 weeks.
Time to Effect
1-3 months
Treatment Duration
until progression or unacceptable toxicity (months to 2 years)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$10,000
Side Effect Mgmt:$5,000
Total Annual:$165,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.35
Outcome-Based Costs
Cost per Responder
$825,000
Cost per Remission
$5,500,000
Immunotherapy (e.g., Pembrolizumab, Nivolumab) Outcomes
for Esophageal Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+20%
Remission Rate
+3%
Common Side Effects
Fatigue
+40%
Rash
+20%
Diarrhea/Colitis (immune-related)
+10%
Endocrinopathies (e.g., Hypothyroidism)
+7%
Pneumonitis (immune-related)
+3%
Hepatitis (immune-related)
+3%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov